FAF
ALNY icon

Första AP-fonden’s Alnylam Pharmaceuticals ALNY Stock Holding History

Första AP-fonden’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,420
Closed -$18.5M – 26
2025
Q4 		$18.5M Buy
46,420
+18,520
+66% +$8.2M 0.11% 166
2025
Q3 		$12.7M Buy
27,900
+1,500
+6% +$611K 0.08% 222
2025
Q2 		$8.61M Buy
26,400
+600
+2% +$166K 0.06% 288
2025
Q1 		$6.97M Sell
25,800
-29,000
-53% -$7.45M 0.05% 312
2024
Q4 		$12.9M Buy
54,800
+3,900
+8% +$1.03M 0.09% 204
2024
Q3 		$14M Buy
50,900
+25,700
+102% +$6.69M 0.11% 184
2024
Q2 		$6.12M Sell
25,200
-43,100
-63% -$6.8M 0.05% 313
2024
Q1 		$10.2M Buy
68,300
+45,500
+200% +$7.59M 0.09% 235
2023
Q4 		$4.36M Sell
22,800
-2,600
-10% -$443K 0.04% 382
2023
Q3 		$4.5M Buy
25,400
+500
+2% +$95.4K 0.05% 368
2023
Q2 		$4.73M Sell
24,900
-900
-3% -$178K 0.05% 375
2023
Q1 		$5.17M Sell
25,800
-2,800
-10% -$589K 0.06% 337
2022
Q4 		$6.8M Buy
28,600
+5,500
+24% +$1.17M 0.08% 311
2022
Q3 		$4.62M Sell
23,100
-5,900
-20% -$1.13M 0.06% 361
2022
Q2 		$4.23M Buy
29,000
+5,700
+24% +$809K 0.06% 375
2022
Q1 		$3.81M Sell
23,300
-500
-2% -$76.2K 0.04% 433
2021
Q4 		$4.04M Buy
23,800
+500
+2% +$92.9K 0.04% 434
2021
Q3 		$4.4M Buy
23,300
+9,900
+74% +$1.86M 0.05% 420
2021
Q2 		$2.27M Sell
13,400
-11,600
-46% -$1.7M 0.03% 485
2021
Q1 		$3.53M Buy
25,000
+1,600
+7% +$241K 0.05% 436
2020
Q4 		$3.04M Buy
23,400
+4,800
+26% +$641K 0.05% 424
2020
Q3 		$2.71M Buy
18,600
+4,100
+28% +$583K 0.06% 373
2020
Q2 		$2.15M Sell
14,500
-1,700
-10% -$229K 0.06% 352
2020
Q1 		$1.76M Buy
+16,200
New +$1.87M 0.06% 355

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Första AP-fonden's ALNY Position: Q1 2026 in Review

Första AP-fonden sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 46,420 shares — an estimated $18.5M sold.

Första AP-fonden first reported a position in ALNY in Q1 2020 and held it in 24 quarters. The position peaked at $18.5M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Första AP-fonden reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Första AP-fonden sold 46,420 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $18.5M.
  • Första AP-fonden first reported a position in Alnylam Pharmaceuticals in Q1 2020 and held it in 24 quarters.
  • Första AP-fonden's Alnylam Pharmaceuticals position peaked at $18.5M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Första AP-fonden's 13F filing for Q1 2026.